Blog

Peter Lebowitz: Three Phase 3 lung cancer readouts in the Presidential Symposium and 4 late-breaker presentations in genitourinary cancers

Photo taken from: Peter Lebowitz/LinkedIn

Oct 21, 2023, 23:53

Peter Lebowitz: Three Phase 3 lung cancer readouts in the Presidential Symposium and 4 late-breaker presentations in genitourinary cancers

Peter Lebowitz, SVP, Global Oncology Therapeutic Area Head at Janssen/Johnson and Johnson, made the following post on LinkedIn:

“Three Phase 3 lung cancer readouts in the Presidential Symposium and 4 late-breaker presentations in genitourinary cancers (bladder cancer and prostate cancer).

It’s great to be on the ground at ESMO – European Society for Medical Oncology in Madrid with our best-in-industry Johnson & Johnson Innovative Medicine Oncology team seeing first-hand the advances in solid tumor science and innovation for patients.”

Source: Peter Lebowitz/LinkedIn

cancer clinical trials ESMO - European Society for Medical Oncology Johnson & Johnson Innovative Medicine Oncology OncoDaily Oncology Peter Lebowitz Research

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage